Benzothiazepines

Abstract: Certain 1,5-benzothiazepines are useful intermediates or pharmaceuticals.

Description: This invention concerns benzothiazepines, useful as intermediates or pharmaceuticals. Various useful benzothiazepines are known. See, patents classified in U.S. Patent class 540 subclass 491, e.g., US-A-3,075,967, 3,562,257, 4,512,988, 4,567,175, 4,584,131, GB-A-2,143,532, US-A-4,694,002 and FR-A-1,552,840. Here diltiazem and related 1,5 benzothiazepine compounds are described. Such art discloses that these compounds are useful, as may be appropriate, as drugs for the treatment of Parkinsonism, as antidepressants, as tranquilizers, as coronary vasodilators, as hypotensive agents, as cerebral vasodilators, as antiarrhythmic agents, as anti-anginal agents, as antifibrillatory agents, as anti-asthmatic agents, and in limiting myocardial infarction. The art lacks and needs further benzothiazepines, to include those having other uses. Provided is a Compound/Salt, i.e., a compound, or salt thereof, or compound salt, selected from among those represented by the following general formula: further being identified as follows: Compound/Salt Q R R' R'' cis-ML1078 H pCF3 H R''1a cis-ML1080 H pOMe adamantylcarboxy R''1a cis-ML1082 H pCF3 H R''5 trans-ML1096 8-Cl pOMe H R''5 trans-ML1103 H pOMe H R''5 with R''1a being 2-(dimethylamino)ethyl and R''5 being 2-(piperidino)ethyl These are useful intermediates or pharmaceuticals, which can possess activity as antidepressants, tranquilizers and/or coronary vasodilators. Furthermore, certain of these surprisingly are effective, even excellent, anti-cancer drug potentiators, e.g. cis-ML1078, cis-ML1082, trans-ML1096 and especially trans-ML1103, and/or excellent ameliorators for generalized tonic-clonic epileptic type seizures in mammals, e.g., cis-ML1078, cis-ML1082 and trans-ML1096. The compounds and compound salts of this invention can be made by reacting a suitable glycidic acid ester with a suitable aminothiophenol to prepare corresponding aminophenylthiopropionic acid ester, then cyclyzing the latter ester or its corresponding free acid, followed by N-alkylation and 3-acylation as may be desired. Suitable glycidic acid esters may be found in the prior art, or they can be prepared by other methods; see e.g., US-A-4,885,375. Compound/Salts can be prepared by N-alkylation of known 5-hydro-1,5-benzothiazepin-4(5H)-ones; see e.g. US-A-3,562,257 and 4,567,175. On the one hand, the benzothiazepine compounds of this invention may be present as a free or neutral amino compound. Alternatively, they may be present as a salt thereof, typically where an alkyl amino nitrogen is cationic and a suitable anion accompanies this salt. Salts of the benzothiazepine compounds of this invention include suitable pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts generally include such salts as the hydrochloride, the fumarate, the sulfate, the citrate, the maleate, and so forth. The following examples further illustrate this invention. In the examples, parts, percentages and ratios are by weight. Example 1 A. Preparation of dl-cis-ML1078 & 1082 intermediates: To 150 mL of dry methanol was added 3.93 g of sodium (0.121 mol). Slowly with stirring, to the freshly made sodium methoxide solution was added 24.72 g of 4-trifluoromethylbenzaldehyde (0.142 mol) and a solution of 18.55 g of methyl chloroacetate (0.171 mol) in 75 mL of dry methanol. After stirring for 2 hours at 0 degrees C., the resulting reaction mixture was poured onto ice and extracted with ethyl acetate. The ethyl acetate layer was dried and concentrated to give 24.6 g of a product of dl-trans-(4-trifluoromethylphenyl)glycidic acid methyl ester. All of the dl-trans-(4-trifluoromethylphenyl)glycidic acid methyl ester (0.1 mol) and 12.5 g of 2-aminothiophenol (0.1 mol) were refluxed in 120 mL of toluene overnight. Cooling of the resulting reaction mixture in a freezer for 3 hours provided a precipitate, which was filtered, washed with an ice-cold 1:1 solution of hexane to ethyl acetate, and dried under vacuum to give 15.0 g of a product of dl-threo-2-hydroxy-3-(2-aminophenylthio)-3-(4-trifluoromethylphenyl)propionic acid methyl ester. All of the dl-threo-2-hydroxy-3-(2-aminophenylthio)-3-(4-trifluoromethylphenyl)propionic acid methyl ester (0.0416 mol) was saponified with 3.0 g of potassium hydroxide (0.054 mol) by boiling a mixture of these in 100 mL of water for 45 minutes. The resulting mixture was then cooled with an ice bath, and the pH was adjusted to from 3.5 to 4.0 with 6 N aqueous hydrochloric acid. A white precipitate was collected by filtration and washed with 100 mL of water. The solid was placed in a 500-mL flask and refluxed in 150 mL of xylene for 6 hours, with water removed with a Dean-Stark trap. Cooling, to include in an ice bath, resulted in precipitation. The precipitate was collected by filtration and dried under vacuum to give 9.6 g of dl-cis-2-(4-trifluoromethylphenyl)-2,3-dihydro-3-hydroxy-1,5-benzothiazepin-4(5H)-one. B. Preparation of dl-cis-ML1078: A 2.0 g sample of the dl-cis-2,3-dihydro-2-(4-trifluoromethylphenyl)-3-hydroxy-1,5-benzothiazepin-4(5H)-one from part A above (5.9 mmol) was dissolved in 70 mL of ethyl acetate; 1.35 g of 1-chloro-2-(N-dimethylamino)ethane hydrochloride (9.4 mmol), 1.65 g of potassium carbonate (12.0 mmol) and 3 mL of water were added, and the resulting mixture was refluxed overnight. The resulting reaction mixture was cooled, extracted with water and then brine, and the organic layer was dried over anhydrous sodium sulfate and concentrated. The concentrated material was taken up with diethyl ether, and anhydrous hydrogen chloride gas was passed therethrough. A white precipitate formed, which was filtered, collected and dried under vacuum to yield 2.0 g of dl-cis-2-(4-trifluoromethylphenyl)-2,3-dihydro-3-hydroxy-5-[2-(N-dimethylamino)ethyl]-1,5-benzothiazepin-4(5H)-one hydrochloride (salt). C. Preparation of dl-cis-ML1082: A 1.0 g sample of the dl-cis-2,3-dihydro-2-(4-trifluoromethylphenyl)-3-hydroxy-1,5-benzothiazepin-4(5H)-one from part A above (3.0 mmol) was dissolved in 50 mL of ethyl acetate; 0.88 g of 1-(2-chloroethyl)piperidine monohydrochloride (4.8 mmol), 1.2 g of potassium carbonate (9.0 mmol) and 4 mL of water were added, and the resulting mixture was refluxed overnight. The resulting reaction mixture was cooled, extracted with water and then brine, and the organic layer was dried over anhydrous sodium sulfate and concentrated. This concentrated material was dissolved in a solvent of 9:1 dichloromethane to ethanol and applied to a column containing 25 g of 230:400 mesh silica gel, which was eluted with a solvent of 9:1 dichloromethane to ethanol. The eluent was concentrated; the concentrated eluent was taken up with toluene, and anhydrous hydrogen chloride gas was passed therethrough. A white precipitate formed, which was filtered, collected and dried under vacuum to yield 1.13 g of dl-cis-2-(4-trifluoromethylphenyl)-2,3-dihydro-3-hydroxy-5-[2-(N-piperidino)ethyl]-1,5-benzothiazepin-4(5H)-one hydrochloride (salt). Example 2 Preparation of dl-cis-ML1080: A mixture of 5.0 g of dl-cis-2-(4-methoxyphenyl)-2,3-dihydro-3-hydroxy-5-[2-(N-dimethylamino)ethyl]-1,5-benzothiazepin-4(5H)-one (13.4 mmol) and 3.45 g of adamantylcarboxylic acid chloride (17.4 mmol) in 30 mL of pyridine was cooled to 0 degrees C. and placed in a refrigerator overnight. The resulting reaction mixture was concentrated, taken up in dichloromethane and extracted thus with water and then brine, then dried over anhydrous sodium sulfate, and concentrated to an oil. The oil was dissolved in dichloromethane and applied to silica gel, which was eluted with a solvent of 9:1 dichloromethane to ethanol. The eluent was concentrated and taken up with ethyl acetate. A sample of 1.5 g of fumaric acid (13.4 mmol) was added, and the resulting mixture was heated to dissolution, adding 1.0 mL of ethanol. The solution was concentrated and vacuum dried for 36 hours to yield dl-cis-2-(4-methoxyphenyl)-2,3-dihydro-3-adamantylcarboxy-5-[2-(N-dimethylamino)ethyl]-1,5-benzothiazepin-4(5H)-one fumarate (salt). Example 3 Preparation of dl-trans-ML1096: To a 100-mL round bottom flask was added 1.98 g of dl-trans-2-(4-methoxyphenyl)-2,3-dihydro-3-hydroxy-8-chloro-1,5-benzothiazepin-4(5H)-one (5.9 mmol), then 16 mL of ethyl acetate and 1.0 mL of water, next 1.19 g of 1-(2-chloroethyl)piperidine monohydrochloride (6.5 mmol) and 1.80 g of anhydrous potassium carbonate (13.0 mmol). The resulting mixture was stirred at about 77 degrees C. for 17-1/4 hours, cooled to room temperature, washed well three times with water, and the organic layer was concentrated to obtain about 3 g of a beige colored solid. The solid was taken up with 2-butanone; anhydrous hydrogen chloride gas was passed therethrough, and solvent was removed, giving an oily solid. Mixing with ether gave 2.62 g of salt product, which was dried. A 0.531 g sample of the salt product was dissolved in a heated mixture of about 7 mL of reagent ethanol and 4 mL of trichloromethane. The addition of 23 mL of ether and cooling in ice gave solid product, which was filtered, rinsed well with ether and dried to yield a first crop of 0.373 g. The remaining salt product, about 2.089 g, was dissolved in a heated mixture of 28 mL of reagent ethanol and 16 mL of trichloromethane. The addition of 90 mL of ether, stirring at room temperature and cooling in ice gave solid product, which was filtered, rinsed with ether and dried to yield a second crop of 1.492 g. The total yield of dl-trans-2-(4-methoxyphenyl)-2,3-dihydro-3-hydroxy-5-[2-(N-piperidino)ethyl]-8-chloro-1,5-benzothiazepin-4(5H)-one hydrochloride (salt) was 1.865 g (65.2 percent of theory). HPLC analysis indicated 98.4 percent purity. Elemental analysis of the first crop, Calculated: C, 57.14; H, 5.84; O, 9.93; N, 5.79; S, 6.63; Cl, 14.67. Found: C, 56.84; 56.82. H, 5.74; 5.75. N, 5.65; 5.63. S, 6.15; 6.27. Cl, 15.08; 15.13. Example 4 Preparation of dl-trans-ML1103: Refluxed overnight was a mixture of 2.0 g of dl-trans-2-(4-methoxyphenyl)-2,3-dihydro-3-hydroxy-1,5-benzothiazepin-4(5H)-one (6.64 mmol), 5.4 g of 1-(2-chloroethyl)piperidine monohydrochloride (29 mmol), 7.1 g of anhydrous potassium carbonate (51 mmol), 74.8 mL of ethyl acetate, and 6.6 mL of water. The resulting mixture was cooled, washed with water and then brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. A silica gel column chromatographic purification using an eluent of a 9:1 ethyl acetate to ethanol solution was performed, and solvent was removed from cuts containing product under vacuum. Product was dissolved in 200 mL of toluene, and anhydrous hydrogen chloride gas was passed therethrough. The resulting mixture was concentrated, and salt product was recrystallized from ethanol, filtered, rinsed with ether and dried under vacuum to yield dl-trans-2-(4-methoxyphenyl)-2,3-dihydro-3-hydroxy-5-[2-(N-piperidino)ethyl]-1,5-benzothiazepin-4(5H)-one hydrochloride (salt).

Claims: A Compound/Salt represented by the following general formula: further being identified as follows: Compound/Salt Q R R' R'' cis-ML1078 H pCF3 H R''1a, cis-ML1080 H pOMe adamantylcarboxy R''1a, cis-ML1082 H pCF3 H R''5, trans-ML1096 8-Cl pOMe H R''5 or trans-ML1103 H pOMe H R''5 with R''1a being 2-(dimethylamino)ethyl and R''5 being 2-(piperidino)ethyl. The Compound/Salt of claim 1, which is cis-ML1078. The Compound/Salt of claim 1, which is cis-ML1080. The Compound/Salt of claim 3, which is a fumarate salt. The Compound/Salt of claim 1, which is cis-ML1082. The Compound/Salt of claim 1, which is trans-ML1096. The Compound/Salt of claim 1, which is trans-ML1103. The Compound/Salt of any one of claims 2, 5, 6 or 7, which is a hydrochloride salt. A Compound/Salt of the general formula I according to claim 1 for use as a pharmaceutically active agent. A method for the preparation of a compound according to any one of claims 1-8 which comprises reacting a suitable glycidic acid ester with a suitable aminothiophenol to prepare corresponding aminophenylthiopropionic acid ester, then cyclyzing the latter ester or its corresponding free acid, followed by N-alkylation and 3-acylation as may be desired. A method for the preparation of a pharmaceutical composition comprising combining a compound according to any one of claims 1-8 with a pharmaceutically acceptable carrier.

Inventors: BORCHERDING DAVID R, MARTIN DANIEL E, BORCHERDING, DAVID R., MARTIN, DANIEL E.
Applicants: MARION MERRELL DOW INC, MARION MERRELL DOW INC.
Application year: 1990
Main classification: C07D281
IPC codes: C07D281, A61K31, C07D417, A61P43, A61P25, A61P9, A61P35